HK1210173A1 - Substituted 6-amino-nicotinamides bearing an oh-containing group as kcnq2/3 modulators - Google Patents

Substituted 6-amino-nicotinamides bearing an oh-containing group as kcnq2/3 modulators Download PDF

Info

Publication number
HK1210173A1
HK1210173A1 HK15111080.1A HK15111080A HK1210173A1 HK 1210173 A1 HK1210173 A1 HK 1210173A1 HK 15111080 A HK15111080 A HK 15111080A HK 1210173 A1 HK1210173 A1 HK 1210173A1
Authority
HK
Hong Kong
Prior art keywords
nicotinamides
amino
substituted
bearing
containing group
Prior art date
Application number
HK15111080.1A
Other languages
English (en)
Chinese (zh)
Inventor
Simon Lucas
Sven KÜHNERT
Gregor Bahrenberg
Wolfgang Schröder
Achim Kless
Original Assignee
Grünenthal GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Grünenthal GmbH filed Critical Grünenthal GmbH
Publication of HK1210173A1 publication Critical patent/HK1210173A1/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355Non-condensed oxazines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81Amides; Imides
    • C07D213/82Amides; Imides in position 3

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
HK15111080.1A 2012-04-18 2013-04-17 Substituted 6-amino-nicotinamides bearing an oh-containing group as kcnq2/3 modulators HK1210173A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12002709 2012-04-18
EP12002709.9 2012-04-18
PCT/EP2013/001134 WO2013156154A1 (en) 2012-04-18 2013-04-17 Substituted 6-amino-nicotinamides bearing an oh-containing group as kcnq2/3 modulators

Publications (1)

Publication Number Publication Date
HK1210173A1 true HK1210173A1 (en) 2016-04-15

Family

ID=48227140

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15111080.1A HK1210173A1 (en) 2012-04-18 2013-04-17 Substituted 6-amino-nicotinamides bearing an oh-containing group as kcnq2/3 modulators

Country Status (21)

Country Link
EP (1) EP2888233B1 (https=)
JP (1) JP6033403B2 (https=)
CN (1) CN104428287A (https=)
AR (1) AR090739A1 (https=)
AU (1) AU2013248637A1 (https=)
BR (1) BR112014025840A2 (https=)
CA (1) CA2870573A1 (https=)
CY (1) CY1118255T1 (https=)
DK (1) DK2888233T3 (https=)
EA (1) EA201401142A1 (https=)
ES (1) ES2605947T3 (https=)
HK (1) HK1210173A1 (https=)
HR (1) HRP20161424T1 (https=)
HU (1) HUE030859T2 (https=)
IL (1) IL235030A0 (https=)
LT (1) LT2888233T (https=)
MX (1) MX2014012494A (https=)
PT (1) PT2888233T (https=)
RS (1) RS55466B1 (https=)
SI (1) SI2888233T1 (https=)
WO (1) WO2013156154A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201809184VA (en) * 2016-04-22 2018-11-29 Ono Pharmaceutical Co Crystal polymorphism of kcnq2-5 channel activator
JP7262468B2 (ja) * 2017-12-29 2023-04-21 スリーエム イノベイティブ プロパティズ カンパニー 熱硬化性2剤型加工用接着剤組成物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2230392A1 (de) 1972-06-22 1974-01-31 Cassella Farbwerke Mainkur Ag Substituierte pyridinverbindungen und verfahren zu ihrer herstellung
DE2513949A1 (de) 1975-03-29 1976-10-07 Bayer Ag Azofarbstoffe
CA2438868A1 (en) 2001-02-20 2002-09-19 Valentin K. Gribkoff Modulators of kcnq potassium channels and use thereof in treating migraine and mechanistically related diseases
US20020183335A1 (en) * 2001-02-20 2002-12-05 Piyasena Hewawasam 2, 4-disubstituted pyrimidine-5-carboxamide derivatives as KCNQ potassium channel modulators
EP2086935A1 (de) * 2006-10-16 2009-08-12 Grünenthal GmbH Substituierte sulfonamid-derivate als bradykinin 1 rezeptor modulatoren
DE102006049452A1 (de) 2006-10-17 2008-05-08 Grünenthal GmbH Substituierte Tetrahydropyrolopiperazin-Verbindungen und deren Verwendung in Arzneimitteln
HRP20120822T1 (hr) 2008-10-24 2012-11-30 Grünenthal GmbH Supstituirani 4,5,6,7-tetrahidrotienopiridini kao kcnq2/3 modulatori za lijeäśenje boli, epilepsije i urinarne inkontinencije
TWI475020B (zh) 2009-03-12 2015-03-01 The substituted nicotine amide as a KCNQ2 / 3 modifier
PE20140199A1 (es) * 2010-10-20 2014-02-16 Gruenenthal Chemie 6-amino-nicotinamidas sustituidas como moduladores de kcnq2/3

Also Published As

Publication number Publication date
ES2605947T3 (es) 2017-03-17
EP2888233A1 (en) 2015-07-01
DK2888233T3 (en) 2017-01-09
HUE030859T2 (en) 2017-06-28
MX2014012494A (es) 2015-01-15
JP6033403B2 (ja) 2016-11-30
SI2888233T1 (sl) 2016-12-30
RS55466B1 (sr) 2017-04-28
CY1118255T1 (el) 2017-06-28
CA2870573A1 (en) 2013-10-24
BR112014025840A2 (pt) 2017-07-18
EA201401142A1 (ru) 2015-03-31
LT2888233T (lt) 2017-01-10
EP2888233B1 (en) 2016-09-28
CN104428287A (zh) 2015-03-18
PT2888233T (pt) 2017-01-04
JP2015514728A (ja) 2015-05-21
AU2013248637A1 (en) 2014-12-04
WO2013156154A1 (en) 2013-10-24
HRP20161424T1 (hr) 2016-12-16
IL235030A0 (en) 2014-12-31
AR090739A1 (es) 2014-12-03

Similar Documents

Publication Publication Date Title
MX2013004329A (es) 6-amino-nicotinamidas sustituidas como moduladores de kcnq2/3.
WO2014106238A8 (en) Heterocyclic compounds and methods of use thereof
MX2013011908A (es) Composiciones y usos terapeuticos de inhibidores de cinasa epsilon relacionados con cinasa i-kappa b (ikk) y cinasa 1 de union tank.
WO2013163190A8 (en) Dna-pk inhibitors
WO2015001504A3 (en) Antibody formulations and methods
MX2015012502A (es) Inhibidores de proteina cinasa dependiente de adn.
HK1213264A1 (zh) 经取代的苯化合物
PH12013502240B1 (en) Novel compounds as modulators of protein kinase
WO2013013815A8 (en) Substituted heteroaromatic pyrazole-containing carboxamide and urea derivatives as vanilloid receptor ligands
HK1206028A1 (en) Phenicol antibacterials
EP4414376A3 (en) Novel depsipeptide and uses thereof
WO2015015378A3 (en) Heterobicycloaryl rorc2 inhibitors and methods of use thereof
MX361349B (es) Moduladores del receptor x del higado (lxr) para el tratamiento de enfermedades, trastornos y condiciones dérmicas.
MX2014000964A (es) Derivados aza heterociclicos sustituidos.
WO2015059463A3 (en) Treatment of beta-catenin related diseases8
MX2013011421A (es) Derivados de pirazolo-pirimidina.
MX2013002118A (es) 2-oxi-quinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3.
HK1258456A1 (zh) 吡唑基取代的四氢吡喃碸
WO2014035846A3 (en) Substituted azaindole compounds, salts, pharmaceutical compositions thereof and methods of use
MX2013002121A (es) Quinolina-3-carboxamidas sustituidas como moduladores de kcnq2/3.
MX366829B (es) Composiciones y formas de dosificacion de itraconazol y metodos de uso de las mismas.
WO2011014520A3 (en) Compounds and compositions as modulators of gpr119 activity
MX2013002119A (es) Sustituidas-2-oxo- y 2-tioxo-dihidroquinolin-3-carboxamidas como moduladores de kcnq2/3.
HK1258461A1 (zh) 吡唑基取代的四氢吡喃碸
MX2016007955A (es) Pirrol carboxamidas iii fluorometil-sustituidas.